Monday, May 07, 2018 2:38:02 PM
Yes sir! Maybe we get a small pullback but all dips being bought so it’s hard to add without slapping the offer lol. Those on sidelines will have to chase this since there really are no sellers on the tape. Plus the issue is timing the news. It literally could drop any day now so best approach is to accumulate and sit on it. If you flip, you may miss a big run. My 2¢ $AKTX
Recent AKTX News
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2026 08:40:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 08:30:23 PM
- This Emerging Biotech Wave Could Create the Next Monster Healthcare Winners • GlobeNewswire Inc. • 05/22/2026 01:42:40 PM
- Akari Therapeutics Reports Breakthrough Preclinical Data Demonstrating Synergistic Activity of AKTX-101 with KRAS Inhibition in KRAS-Mutated Pancreatic Cancer Models • GlobeNewswire Inc. • 05/21/2026 09:01:00 PM
- Akari Therapeutics Announces $5.5 Million Private Placement Offering • GlobeNewswire Inc. • 05/21/2026 12:30:00 PM
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 05/21/2026 12:15:23 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/19/2026 09:00:50 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/18/2026 09:15:18 PM
- Akari Therapeutics to Present at A.G.P.’s Annual Healthcare Company Showcase • GlobeNewswire Inc. • 05/18/2026 01:05:00 PM
- Akari Therapeutics Secures Key European Patent For Its Novel RNA Splicing Modulator ADC Payload, Strengthening Global IP Estate For All Major Global Markets • GlobeNewswire Inc. • 05/12/2026 12:33:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 05/08/2026 09:08:03 PM
- Akari Therapeutics Secures Australian Patent Approval, Further Expanding Global Protection of Its Proprietary PH1 RNA Splicing Modulator ADC Payload • GlobeNewswire Inc. • 04/27/2026 12:35:00 PM
- Akari Therapeutics ASCO Abstract Acceptance Highlights Potential for AKTX-101 ADC to Treat KRAS Mutant Tumors • GlobeNewswire Inc. • 04/21/2026 01:00:00 PM
- Akari Therapeutics Reports Positive Preclinical Data for AKTX-101 Demonstrating Differentiated Cytotoxicity for First-in-Class TROP2 ADC Payload Targeting RNA Splicing • GlobeNewswire Inc. • 04/20/2026 12:35:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/16/2026 04:15:07 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/10/2026 08:15:02 PM
- Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing Strategic Partnership with WuXi XDC • GlobeNewswire Inc. • 04/09/2026 12:50:00 PM
- Akari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA Splicing • GlobeNewswire Inc. • 04/06/2026 12:45:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/30/2026 09:39:37 PM
- Akari Therapeutics to present ADC research at AACR Annual Meeting 2026 • IH Market News • 03/18/2026 03:02:39 PM
- Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026 • GlobeNewswire Inc. • 03/18/2026 12:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/17/2026 09:07:26 PM
- Akari Therapeutics Announces ADS Ratio Change • GlobeNewswire Inc. • 03/17/2026 08:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/16/2026 09:00:03 PM
- Akari Therapeutics Releases CEO Corner Highlighting Strategic Progress and Path to Clinical Development Under CEO Abizer Gaslightwala • GlobeNewswire Inc. • 03/13/2026 01:15:00 PM
